Cancer News and Research

Latest Cancer News and Research

Folotyn approved for the treatment of Peripheral T-Cell Lymphoma

The U.S. Food and Drug Administration has approved Folotyn (pralatrexate), the first treatment for a form of cancer known as Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.

25 Sep 2009

NIH calls for identifying better methods to predict the risk of developing breast cancer

Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup.

25 Sep 2009

On quality of care, U.S. is not always best

The Washington Post interviewed Sen. Kent Conrad, D-N.D., about other developed nations' health care systems: "We won't adopt the German system or French system or anything of the like. But I think we can get clues on the fundamental differences of various systems," he said. Conrad added that the system that has "largely been adopted in France, Germany, Japan, Belgium and Switzerland, is not government-run.

25 Sep 2009

DOR Biopharma to raise $3.85 million from institutional investors

DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biotechnology company, announced today that it has entered into common stock purchase agreements with institutional investors totaling approximately $3.85 million. DOR's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.

25 Sep 2009

NCI awards Altor Bioscience a $3 MM grant to develop its targeted cancer therapeutic ALT-801

Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its clinical development of ALT-801, a novel tumor-targeted immunotherapeutic designed to improve the efficacy and safety of the FDA-approved anticancer cytokine, interleukin-2 (IL-2).

25 Sep 2009

Susan G. Komen Race for the Cure to raise public awareness about breast cancer

A sea of pink t-shirts will stretch from Athens to Bologna to Frankfurt to Zurich to Antwerp today in an effort to raise public awareness about breast cancer. In five cities across Europe, breast cancer survivors, their families, friends, supporters and advocates will join forces in a show of strength, courage and solidarity.

25 Sep 2009

BSD Medical Corporation announces the filing of shelf registration statement with SEC

BSD Medical Corporation today announced the filing of a shelf registration statement on Form S-3 with the Securities and Exchange Commission.

25 Sep 2009

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

YM BioSciences Inc. a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for its fiscal year end, ended June 30, 2009.

25 Sep 2009

The Siebel Foundation to fund fellowships for Jacob School's top bioengineering graduate students

As breakthrough discoveries in bioengineering become more crucial to fundamental global issues, including health, food production and water supplies, UC San Diego's Jacobs School of Engineering's top ranked bioengineering department continues to be on the cutting edge of this field. The Siebel Foundation has recognized the Jacob School's pioneering efforts with a $2 million endowment to fund fellowships for some of its top bioengineering graduate students.

25 Sep 2009

Three-day meeting to discuss breakthroughs in prostate cancer

Nearly of 300 of the world’s leading researchers focused on the problem of prostate cancer will begin a three-day meeting today to discuss the latest scientific data and breakthroughs in prostate cancer. The meeting, held in Incline Village at Lake Tahoe in Nevada, is the 16th Scientific Retreat sponsored by the Prostate Cancer Foundation (PCF).

25 Sep 2009

Vertex Pharmaceuticals to present SVR data at the 60th Annual Meeting of the American Association

Vertex Pharmaceuticals Incorporated today announced that sustained virologic response (SVR) data from Study C208, which evaluated twice-daily dosing of Vertex’s investigational hepatitis C virus (HCV) protease inhibitor telaprevir, will be presented in an oral presidential plenary session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place Oct. 30 – Nov. 3, 2009 in Boston.

25 Sep 2009

Baylor Health Care receives $20 million donation from Sammons Enterprises

Today the Baylor Health Care System Foundation announced gifts exceeding $20 million for what will be North Texas' largest outpatient cancer center and first dedicated hospital focusing on cancer patients.

25 Sep 2009

$4.5 million cost involved for MLSIC set up

The Michigan Economic Development Corp. (MEDC), Ann Arbor SPARK, Greater Wayne Economic Development Corporation and a private foundation have collaborated to create the Michigan Life Science and Innovation Center (MLSIC). MLSIC will connect well-funded, experienced entrepreneurs with business accelerator organizations and start-up life science companies.

25 Sep 2009

Senior chemist receives nation's highest award for achievement in science

Joanna Fowler, a senior chemist and Director of the Radiotracer Chemistry, Instrumentation and Biological Imaging Program at the U.S. Department of Energy's Brookhaven National Laboratory, will be awarded the National Medal of Science at a White House ceremony on October 7. She is one of nine researchers named by President Barack Obama to receive the nation's highest award for lifetime achievement in science.

25 Sep 2009

Researchers to use Intravenous Immune Globulin for slowing AD progression

Researchers from the Memory and Cognition Center at University Hospitals Case Medical Center will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin.

25 Sep 2009

Research to improve the targeting of chemotherapeutic drugs to specific cells

Kenneth Longmuir, associate professor of physiology & biophysics, and Richard Robertson, professor of anatomy & neurobiology, used liposomes, small spheres (less-than 100 nanometer in diameter) of naturally-occurring lipid molecules, as "packages" for the cancer chemotherapeutic agent doxorubicin, and a small peptide molecule to "address" the package to the targeted tissue.

25 Sep 2009

NIH to award $348 million for investigators to speed the translation of research into improved health

The National Institutes of Health (NIH) announced today that it is awarding $348 million to encourage investigators to explore bold ideas that have the potential to catapult fields forward and speed the translation of research into improved health.

25 Sep 2009

Chemicals found in breast milk adversly affect the fetal testis

A comparison of breast milk samples from Denmark and Finland revealed a significant difference in environmental chemicals which have previously been implicated in testicular cancer or in adversely affecting development of the fetal testis in humans and animals. This finding is published today in the International Journal of Andrology.

25 Sep 2009

Children exposed to pesticides more susceptible to chilhood leukemia

Northern California Cancer Center (NCCC) research reveals that children exposed to agricultural pesticides applied near their home may experience an increased risk of the most common form of childhood leukemia.

25 Sep 2009

$10 million grant to Weill Cornell Institute from NIMH to study geriatric depression

The Weill Cornell Institute of Geriatric Psychiatry at NewYork-Presbyterian Hospital/Westchester Division announced today it has received the largest grant in its 20-year history. One of a handful awarded nationally, the new $10 million, five-year "Center Grant" from the National Institute of Mental Health (NIMH) will enable NewYork-Presbyterian/Weill Cornell investigators to advance their pioneering work in understanding the biological, medical, cognitive and psychosocial problems of depressed seniors.

25 Sep 2009

Cancer News and Research

Latest Cancer News and Research

Folotyn approved for the treatment of Peripheral T-Cell Lymphoma

NIH calls for identifying better methods to predict the risk of developing breast cancer

On quality of care, U.S. is not always best

DOR Biopharma to raise $3.85 million from institutional investors

NCI awards Altor Bioscience a $3 MM grant to develop its targeted cancer therapeutic ALT-801

Susan G. Komen Race for the Cure to raise public awareness about breast cancer

BSD Medical Corporation announces the filing of shelf registration statement with SEC

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

The Siebel Foundation to fund fellowships for Jacob School's top bioengineering graduate students

Three-day meeting to discuss breakthroughs in prostate cancer

Vertex Pharmaceuticals to present SVR data at the 60th Annual Meeting of the American Association

Baylor Health Care receives $20 million donation from Sammons Enterprises

$4.5 million cost involved for MLSIC set up

Senior chemist receives nation's highest award for achievement in science

Researchers to use Intravenous Immune Globulin for slowing AD progression

Research to improve the targeting of chemotherapeutic drugs to specific cells

NIH to award $348 million for investigators to speed the translation of research into improved health

Chemicals found in breast milk adversly affect the fetal testis

Children exposed to pesticides more susceptible to chilhood leukemia

$10 million grant to Weill Cornell Institute from NIMH to study geriatric depression

Cancer Research - Second Edition eBook

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Leveraging the Radian ASAP in standard casework

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Leveraging the Radian ASAP in standard casework

Newsletters you may be interested in